Floatz logo

Mocetinostat

Gastric Cancer

Mirati Therapeutics Inc.Small moleculePhase 1Dormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
19/ 100
Competitive Position
65/ 100

Competitive context

283 Active assets in the Gastric Cancer cohort.

Asset / SponsorPhaseRating
Rivoceranib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 4BBB
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 4BB
Eloxatin
Qilu Pharmaceutical Co., Ltd.
Phase 3BB
Docetaxel
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Qilu Pharmaceutical Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

Mocetinostat is also rated in:

acute myeloid leukemiaDormant
CC
Indicative ·
47 / 100
View asset →
myelodysplastic syndromeDormant
CC
Indicative ·
47 / 100
View asset →
neoplasmDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →